Table 2. Tumor response based on mutation status.
Variable | KRAS mut | Wild-type | P value |
---|---|---|---|
Overall tumor reduction, median (range) | 58% (−257–94%) | 70% (53–100%) | 0.04 |
ORR, n (%) | 7 (64%) | 13 (100%) | 0.03 |
Conversion to resectability, n (%) | 2 (18%) | 8 (62%) | 0.05 |
Progression free survival, months, median (95% CI) | 8.9 (95% CI: 4.7–13.1) | 9.8 (95% CI: 6.4–13.1) | 0.68 |
Hepatic progression free survival, months, median (95% CI) | 20.5 (95% CI: 6.1–34.9) | 12.7 (95% CI: 5.6–19.8) | 0.63 |
ORR, objective response rate.